NO20053529L - Lymfotoksin-beta-reseptormedikamenter i kombinasjon med kjemoterapeutiske midler - Google Patents

Lymfotoksin-beta-reseptormedikamenter i kombinasjon med kjemoterapeutiske midler

Info

Publication number
NO20053529L
NO20053529L NO20053529A NO20053529A NO20053529L NO 20053529 L NO20053529 L NO 20053529L NO 20053529 A NO20053529 A NO 20053529A NO 20053529 A NO20053529 A NO 20053529A NO 20053529 L NO20053529 L NO 20053529L
Authority
NO
Norway
Prior art keywords
combination
beta receptor
lymphotoxin
chemotherapeutic agents
receptor drugs
Prior art date
Application number
NO20053529A
Other languages
English (en)
Norwegian (no)
Other versions
NO20053529D0 (no
Inventor
Doreen Lepage
Aaln Gill
Original Assignee
Biogen Idec Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Biogen Idec Inc filed Critical Biogen Idec Inc
Publication of NO20053529D0 publication Critical patent/NO20053529D0/no
Publication of NO20053529L publication Critical patent/NO20053529L/no

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2878—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39541—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against normal tissues, cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Microbiology (AREA)
  • Biomedical Technology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
NO20053529A 2002-12-20 2005-07-19 Lymfotoksin-beta-reseptormedikamenter i kombinasjon med kjemoterapeutiske midler NO20053529L (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US43518502P 2002-12-20 2002-12-20
PCT/US2003/041243 WO2004058183A2 (en) 2002-12-20 2003-12-22 Lymphotoxin beta receptor agents in combination with chemotherapeutic agents

Publications (2)

Publication Number Publication Date
NO20053529D0 NO20053529D0 (no) 2005-07-19
NO20053529L true NO20053529L (no) 2005-09-20

Family

ID=32682180

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20053529A NO20053529L (no) 2002-12-20 2005-07-19 Lymfotoksin-beta-reseptormedikamenter i kombinasjon med kjemoterapeutiske midler

Country Status (16)

Country Link
US (1) US20060134102A1 (pl)
EP (1) EP1585547A4 (pl)
JP (1) JP2006513225A (pl)
KR (1) KR20050094819A (pl)
CN (1) CN1753692A (pl)
AU (1) AU2003303339A1 (pl)
BR (1) BR0317573A (pl)
CA (1) CA2509495A1 (pl)
EA (1) EA200501019A1 (pl)
IS (1) IS7900A (pl)
MX (1) MXPA05006663A (pl)
NO (1) NO20053529L (pl)
PL (1) PL377611A1 (pl)
RS (1) RS20050481A (pl)
WO (1) WO2004058183A2 (pl)
ZA (1) ZA200505543B (pl)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6312691B1 (en) * 1996-01-26 2001-11-06 Jeffrey L. Browning Lymphotoxin-α/β complexes and anti-lympotoxin-β receptor antibodies as anti-tumor agents
US5925351A (en) 1995-07-21 1999-07-20 Biogen, Inc. Soluble lymphotoxin-β receptors and anti-lymphotoxin receptor and ligand antibodies as therapeutic agents for the treatment of immunological disease
AR035352A1 (es) * 2000-10-13 2004-05-12 Biogen Inc Anticuerpos anti-lt-beta-r humanizados
CA2490280A1 (en) * 2002-07-01 2004-01-08 Human Genome Sciences, Inc. Antibodies that specifically bind to reg iv
CA2491480A1 (en) * 2002-07-01 2004-01-08 Biogen, Inc. Humanized anti-lymphotoxin beta receptor antibodies
EP1583503A4 (en) * 2002-12-20 2006-08-09 Biogen Idec Inc POLYVALENT LYMPHOTOXIN BETA RECEPTOR AGONISTS AND THERAPEUTIC USE THEREOF
WO2005000898A2 (en) * 2003-06-27 2005-01-06 Biogen Idec Ma Inc. Use of hydrophobic-interaction-chromatography or hinge-region modifications for the production of homogeneous antibody-solutions
EP1756162A1 (en) 2004-03-23 2007-02-28 Biogen Idec MA Inc. Receptor coupling agents and therapeutic uses thereof
WO2006074399A2 (en) * 2005-01-05 2006-07-13 Biogen Idec Ma Inc. Multispecific binding molecules comprising connecting peptides
EP2343320B1 (en) 2005-03-25 2017-10-25 GITR, Inc. Anti-gitr antibodies and uses thereof
WO2006125632A2 (en) * 2005-05-24 2006-11-30 Rechtsanwalt Dr. Martin Prager Als Insolvenzverwalter Über Das Vermögen Der Xantos Biomedicine Ag, Pluta Rechtsanwalts Gmbh Agonistic antibodies that bind to the tweak receptor fn14 and thereby modulate adiposity-associated phenotypes as well as their use in therapy
CA2655411A1 (en) * 2006-06-15 2007-12-21 Biogen Idec Ma Inc. Combination therapy employing lymphotoxin beta receptor binding molecules in combination with second agents
NZ576032A (en) 2006-10-12 2012-03-30 Genentech Inc Antibodies to lymphotoxin-alpha
US8338376B2 (en) * 2006-10-20 2012-12-25 Biogen Idec Ma Inc. Compositions comprising variant LT-B-R-IG fusion proteins
MX2009004134A (es) * 2006-10-20 2009-08-12 Biogen Idec Inc Tratamiento de trastornos de desmielinizacion con el receptor de linfotoxina beta soluble.
JP5932217B2 (ja) 2007-07-12 2016-06-08 ジーアイティーアール， インコーポレイテッド Ｇｉｔｒ結合分子を使用する併用療法
MX2018004114A (es) 2015-10-06 2018-08-21 Univ Minnesota Compuestos terapeuticos y metodos.
JOP20190100A1 (ar) 2016-11-19 2019-05-01 Potenza Therapeutics Inc بروتينات ربط مولد ضد مضاد لـ gitr وطرق استخدامها
EP3807401A1 (en) * 2018-06-15 2021-04-21 Universität Bern LIGANDS TO LIGHT OR ITS RECEPTOR LTßR FOR USE IN HAEMATOLOGIC MALIGNANCIES
KR102232659B1 (ko) * 2018-07-16 2021-03-26 전북대학교 산학협력단 항원전달용 폴리펩타이드, 이를 포함하는 Fc-융합 단백질 및 이의 용도
AU2020401755A1 (en) * 2019-12-11 2022-08-04 Cilag Gmbh International Multispecific binding molecules comprising LTBR and EDB binding domains and uses thereof
CN115057938B (zh) * 2022-06-24 2023-01-06 广东菲鹏制药股份有限公司 抗新型冠状病毒人源化多价结合蛋白及其应用

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5618920A (en) * 1985-11-01 1997-04-08 Xoma Corporation Modular assembly of antibody genes, antibodies prepared thereby and use
US5530101A (en) * 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
US5859205A (en) * 1989-12-21 1999-01-12 Celltech Limited Humanised antibodies
PL185364B1 (pl) * 1995-01-26 2003-04-30 Biogen Kompozycje farmaceutyczne do leczenia albo zmniejszenia zaawansowania, ciężkości albo skutków powstawania nowotworu
US6312691B1 (en) * 1996-01-26 2001-11-06 Jeffrey L. Browning Lymphotoxin-α/β complexes and anti-lympotoxin-β receptor antibodies as anti-tumor agents
US5925351A (en) * 1995-07-21 1999-07-20 Biogen, Inc. Soluble lymphotoxin-β receptors and anti-lymphotoxin receptor and ligand antibodies as therapeutic agents for the treatment of immunological disease
PT954333E (pt) * 1996-10-25 2006-10-31 Biogen Idec Inc Receptores soluveis de linfotoxina-beta, anticorpos de receptores de anti-linfotoxina e anticorpos de ligandos de anti-linfotoxina como agentes terapeuticos para o tratamento de doencas imunologicas
US7060667B1 (en) * 1998-01-30 2006-06-13 Biogen Idec Ma, Inc. Treatment of follicular lymphomas using inhibitors of the LT pathway
US7442776B2 (en) * 1999-10-08 2008-10-28 Young David S F Cancerous disease modifying antibodies
AR035352A1 (es) * 2000-10-13 2004-05-12 Biogen Inc Anticuerpos anti-lt-beta-r humanizados
US7361343B2 (en) * 2003-01-21 2008-04-22 Arius Research Inc. Cytotoxicity mediation of cells evidencing surface expression of CD63
CA2491480A1 (en) * 2002-07-01 2004-01-08 Biogen, Inc. Humanized anti-lymphotoxin beta receptor antibodies
EP1583503A4 (en) * 2002-12-20 2006-08-09 Biogen Idec Inc POLYVALENT LYMPHOTOXIN BETA RECEPTOR AGONISTS AND THERAPEUTIC USE THEREOF
US7393531B2 (en) * 2003-01-21 2008-07-01 Arius Research Inc. Cytotoxicity mediation of cells evidencing surface expression of MCSP
EP1756162A1 (en) * 2004-03-23 2007-02-28 Biogen Idec MA Inc. Receptor coupling agents and therapeutic uses thereof

Also Published As

Publication number Publication date
ZA200505543B (en) 2006-12-27
EA200501019A1 (ru) 2006-06-30
EP1585547A2 (en) 2005-10-19
PL377611A1 (pl) 2006-02-06
MXPA05006663A (es) 2005-09-30
EP1585547A4 (en) 2006-10-25
CN1753692A (zh) 2006-03-29
AU2003303339A1 (en) 2004-07-22
WO2004058183A2 (en) 2004-07-15
IS7900A (is) 2005-06-20
US20060134102A1 (en) 2006-06-22
KR20050094819A (ko) 2005-09-28
CA2509495A1 (en) 2004-07-15
JP2006513225A (ja) 2006-04-20
RS20050481A (en) 2007-08-03
NO20053529D0 (no) 2005-07-19
WO2004058183A3 (en) 2004-12-09
BR0317573A (pt) 2005-11-22

Similar Documents

Publication Publication Date Title
NO20053529L (no) Lymfotoksin-beta-reseptormedikamenter i kombinasjon med kjemoterapeutiske midler
Jensen et al. A juvenile form of postsynaptic hippocampal long‐term potentiation in mice deficient for the AMPA receptor subunit GluR‐A
Han et al. Direct evidence for the role of neuropeptide Y in sympathetic nerve stimulation-induced vasoconstriction
AR047841A1 (es) Metodos y composiciones para el tratamiento de transtornos inmunoinflamatorios
CY1113159T1 (el) Ανταγωνιστες υποδοχεα γλυκαγονης, παρασκευη και θεραπευτικες χρησεις
BRPI0413563A (pt) compostos e composições como inibidores de atividade do receptor de quìnase de tirosina
NO20052496D0 (no) Selekterte CGRP antagonister, fremgangsmater for fremstilling derav og anvendelse derav som medikamenter.
TW200731968A (en) Treatment of nonalcoholic fatty liver disease using cholesterol lowering agents and/or H3 receptor antagonist/inverse agonist
WO2007075555A3 (en) Combination of an h3 antagonist/inverse agonist and an appetite suppressant
Sperr et al. Diagnosis, progression patterns and prognostication in mastocytosis
NO20013641L (no) BAFF, relaterte blokkeringsmidler samt anvendelse derav ved stimulering og inhibering av B-celler og immunoglobuliner iimmunresponser
NO2013017I2 (no) (a)dekstrometorfan eller et farmasøytisk akseptabelt salt derav, for eksempel dekstrometorfanhydrobromid og (b) quinidin eller etfarmasøytisk akseptabelt salt derav, for eksempel quinidinsulfat
NO20050827L (no) Anvendelse av interferon-B ved behandling av nyresvikt
WO2007146414A3 (en) Combination therapy employing lymphotoxin beta receptor binding molecules in combination with second agents
BR0316170A (pt) Combinação, composição farmacêutica, uso de uma combinação, e, método para a profilaxia ou tratamento sinergìstico de câncer
Ifergan et al. Reduced folate carrier protein expression in osteosarcoma: implications for the prediction of tumor chemosensitivity
WO2007095161A3 (en) Methods and compositions for treating disorders associated with increased bone turnover and osteopenia
ES2125567T3 (es) Uso de un antagonista de serotonina en combinacion con un antagonista del receptor de taquiquinina para la fabricacion de un medicamento para la prevencion o el tratamiento de la migraña.
BRPI0412919A (pt) combinação de antagonista de mglur2 e inibidor de ache para o tratamento de distúrbios neurológicos crÈnicos e/ou agudos
DK1509618T3 (da) Autoimmune sygdomme og NADPH-oxidasedefekter
Cunha‐Reis et al. VPAC1 and VPAC2 receptor activation on GABA release from hippocampal nerve terminals involve several different signalling pathways
AR044452A1 (es) Combinacion de un antagonista del receptor p2x7 y un inhibidor del factor de necrosis tumoral alfa
Li et al. Development and characterization of five cell models for chemoresistance studies of human ovarian carcinoma
Boucai et al. Selpercatinib-induced hypothyroidism through off-target inhibition of type 2 iodothyronine deiodinase
WO2008021048A3 (en) Adp-ribosyltransferase based methods and compositions

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application